Welcome!

News Feed Item

Biomarkers Market - Discovery Technologies , Validation Services, Applications & Diseases - Global Trends & Forecasts to 2018

DUBLIN, April 16, 2014 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/btrshd/biomarkers_market) has announced the addition of the "Biomarkers Market - Discovery Technologies , Validation Services, Applications & Diseases - Global Trends & Forecasts to 2018" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )


Biomarkers comprise definite cells, genes, molecules, gene products, enzymes, or hormones which are objectively measured as an indicator of typical biological processes, pathogenic processes, or pharmacologic response to a therapeutic intrusion. Major application areas of biomarkers are early disease diagnosis and prevention, drug target recognition, and drug discovery and development. The global market showcases high growth potential in the near future. This market is expected to grow at a CAGR of 18.5% from 2013 to 2018, to reach $40.8 billion by 2018.

The global market has been segmented into biomarker discovery technologies, biomarker services, applications, and disease indications. The biomarker discovery technologies are classified as omics technology, imaging technology, and bioinformatics. Omics technology, which includes proteomics, genomics, transcriptomics, and metabolomics, accounts for the largest share of the biomarker discovery technology market. The biomarkers services market is classified into sample preparation, assay development, and biomarker validation and testing services. Biomarker applications market has been segmented as drug discovery and development, molecular diagnostics, and personalized medicine. Based on type of diseases, the biomarker disease indication market has been classified as oncology, cardiology, neurology, and other diseases (HIV, renal disorders, diabetes, arthritis, and tuberculosis).

Globally, the biomarkers market is witnessing a transformation and is expected to grow at a high growth rate in the coming years. The growth in the market will be primarily driven by advancements in discovery technologies, government initiatives and grants for biomarker research activities, and rising demand for personalized medicine. The incidence and prevalence of chronic diseases such as cancer, cardiac diseases, and diabetes is increasing globally and hence, it is crucial to develop new preventive and diagnostics treatments. Since, biomarkers play a significant role in development of preventive and diagnostic tests and drugs, the demand of biomarkers is expected to increase rapidly.

Over the past few years, the biomarkers industry has been witnessing increasing number of contracts and partnership agreements among market players for the development of novel biomarkers. Major research on biomarkers is taking place in the field of oncology. Recent developments of companies such as Thermo Fisher Scientific, Inc. (U.S.), QIAGEN N.V. (Netherlands), Roche Diagnostics (Switzerland), Hologic, Inc. (U.S.), and Johnson & Johnson (U.S.) have exhibited inclination towards agreements and partnerships, in accordance to their key strategy to expand their market share and geographical presence.


Key Topics Covered:

1 Introduction

2 Executive Summary

3 Market Overview

4 Global Biomarkers Market, By Discovery Technologies

5 Services Market Of Biomarkers

6 Biomarkers Application Market

7 Biomarkers Indication Market

8 Geographical Analysis

9 Competitive Landscape

10 Company Profiles


Companies Mentioned: 

  • Abbott Laboratories
  • Abcodia Ltd
  • Affymetrix Inc
  • Agilent Technologies Inc
  • Amgen Inc
  • Astrazeneca Plc
  • Augurex Life Sciences Corp
  • Aushon Biosystems Inc
  • BGI
  • Bayer Ag
  • Beckman Coulter Inc
  • Biocrates Life Sciences AG
  • Biomarkers Strategies
  • Biosystems International
  • Bristol-Myers Squibb
  • Caprion Proteomics Inc
  • Crescendo Bioscience
  • Eisai Co Ltd
  • Epiontis GMBH
  • Epistem Holdings PLC
  • Eurogentec SA
  • Evotec AG
  • Glaxosmithkline PLC
  • Ipsen
  • Johnson & Johnson
  • Merck & Co
  • Micromedic Technologies Ltd
  • Myriad Genetics Inc
  • Nextgen Sciences Inc
  • Novartis International AG
  • Ocimum Biosolutions Ltd
  • Pacific Biomarkers Inc
  • Pfizer Inc
  • Pronota NV
  • Proteome Sciences Plc
  • Qiagen Nv
  • Quintiles Transnational Corporation
  • Roche Diagnostics Limited
  • Sanofi-Aventis
  • Siemens Healthcare
  • Trans-Hit Biomarkers Inc
  • Vermillion Inc



For more information visit http://www.researchandmarkets.com/research/btrshd/biomarkers_market


Media Contact: Laura Wood , +353-1-481-1716, [email protected]


SOURCE Research and Markets

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
We all know that end users experience the internet primarily with mobile devices. From an app development perspective, we know that successfully responding to the needs of mobile customers depends on rapid DevOps – failing fast, in short, until the right solution evolves in your customers' relationship to your business. Whether you’re decomposing an SOA monolith, or developing a new application cloud natively, it’s not a question of using microservices - not doing so will be a path to eventual ...
DXWorldEXPO LLC announced today that ICC-USA, a computer systems integrator and server manufacturing company focused on developing products and product appliances, will exhibit at the 22nd International CloudEXPO | DXWorldEXPO. DXWordEXPO New York 2018, colocated with CloudEXPO New York 2018 will be held November 11-13, 2018, in New York City. ICC is a computer systems integrator and server manufacturing company focused on developing products and product appliances to meet a wide range of ...
Michael Maximilien, better known as max or Dr. Max, is a computer scientist with IBM. At IBM Research Triangle Park, he was a principal engineer for the worldwide industry point-of-sale standard: JavaPOS. At IBM Research, some highlights include pioneering research on semantic Web services, mashups, and cloud computing, and platform-as-a-service. He joined the IBM Cloud Labs in 2014 and works closely with Pivotal Inc., to help make the Cloud Found the best PaaS.
We all know that end users experience the Internet primarily with mobile devices. From an app development perspective, we know that successfully responding to the needs of mobile customers depends on rapid DevOps – failing fast, in short, until the right solution evolves in your customers' relationship to your business. Whether you’re decomposing an SOA monolith, or developing a new application cloud natively, it’s not a question of using microservices – not doing so will be a path to eventual b...
Sanjeev Sharma Joins November 11-13, 2018 @DevOpsSummit at @CloudEXPO New York Faculty. Sanjeev Sharma is an internationally known DevOps and Cloud Transformation thought leader, technology executive, and author. Sanjeev's industry experience includes tenures as CTO, Technical Sales leader, and Cloud Architect leader. As an IBM Distinguished Engineer, Sanjeev is recognized at the highest levels of IBM's core of technical leaders.
Headquartered in Plainsboro, NJ, Synametrics Technologies has provided IT professionals and computer systems developers since 1997. Based on the success of their initial product offerings (WinSQL and DeltaCopy), the company continues to create and hone innovative products that help its customers get more from their computer applications, databases and infrastructure. To date, over one million users around the world have chosen Synametrics solutions to help power their accelerated business or per...
Dion Hinchcliffe is an internationally recognized digital expert, bestselling book author, frequent keynote speaker, analyst, futurist, and transformation expert based in Washington, DC. He is currently Chief Strategy Officer at the industry-leading digital strategy and online community solutions firm, 7Summits.
In an era of historic innovation fueled by unprecedented access to data and technology, the low cost and risk of entering new markets has leveled the playing field for business. Today, any ambitious innovator can easily introduce a new application or product that can reinvent business models and transform the client experience. In their Day 2 Keynote at 19th Cloud Expo, Mercer Rowe, IBM Vice President of Strategic Alliances, and Raejeanne Skillern, Intel Vice President of Data Center Group and ...
Founded in 2000, Chetu Inc. is a global provider of customized software development solutions and IT staff augmentation services for software technology providers. By providing clients with unparalleled niche technology expertise and industry experience, Chetu has become the premiere long-term, back-end software development partner for start-ups, SMBs, and Fortune 500 companies. Chetu is headquartered in Plantation, Florida, with thirteen offices throughout the U.S. and abroad.
At the keynote this morning we spoke about the value proposition of Nutanix, of having a DevOps culture and a mindset, and the business outcomes of achieving agility and scale, which everybody here is trying to accomplish," noted Mark Lavi, DevOps Solution Architect at Nutanix, in this SYS-CON.tv interview at @DevOpsSummit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
One of the biggest challenges with adopting a DevOps mentality is: new applications are easily adapted to cloud-native, microservice-based, or containerized architectures - they can be built for them - but old applications need complex refactoring. On the other hand, these new technologies can require relearning or adapting new, oftentimes more complex, methodologies and tools to be ready for production. In his general session at @DevOpsSummit at 20th Cloud Expo, Chris Brown, Solutions Marketi...
HyperConvergence came to market with the objective of being simple, flexible and to help drive down operating expenses. It reduced the footprint by bundling the compute/storage/network into one box. This brought a new set of challenges as the HyperConverged vendors are very focused on their own proprietary building blocks. If you want to scale in a certain way, let's say you identified a need for more storage and want to add a device that is not sold by the HyperConverged vendor, forget about it...
In his Opening Keynote at 21st Cloud Expo, John Considine, General Manager of IBM Cloud Infrastructure, led attendees through the exciting evolution of the cloud. He looked at this major disruption from the perspective of technology, business models, and what this means for enterprises of all sizes. John Considine is General Manager of Cloud Infrastructure Services at IBM. In that role he is responsible for leading IBM’s public cloud infrastructure including strategy, development, and offering m...
Historically, some banking activities such as trading have been relying heavily on analytics and cutting edge algorithmic tools. The coming of age of powerful data analytics solutions combined with the development of intelligent algorithms have created new opportunities for financial institutions. In his session at 20th Cloud Expo, Sebastien Meunier, Head of Digital for North America at Chappuis Halder & Co., discussed how these tools can be leveraged to develop a lasting competitive advantage ...
Most companies are adopting or evaluating container technology - Docker in particular - to speed up application deployment, drive down cost, ease management and make application delivery more flexible overall. As with most new architectures, this dream takes a lot of work to become a reality. Even when you do get your application componentized enough and packaged properly, there are still challenges for DevOps teams to making the shift to continuous delivery and achieving that reduction in cost ...